Nucleoside analogues in the therapy of langerhans cell histiocytosis: A survey of members of the histiocyte society and review of the literature

Medical and Pediatric Oncology

Volumn 33, Issue 5, 1999, Pages 476-481

  Weitzman, Sheila ^a   Wayne, Alan S ^b   Arceci, Robert ^c   Lipton, Jeffrey M ^d   Whitlock, James A ^e   De Rossi, Giulio ^f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

2 CdA; Langerhans cell histiocytosis; Salvage therapy

Indexed keywords

CLADRIBINE; NUCLEOSIDE ANALOG; PENTOSTATIN;

ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HISTIOCYTOSIS; HUMAN; IMMUNE DEFICIENCY; KIDNEY TUBULE ACIDOSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CLADRIBINE; DATA COLLECTION; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; LIVER; MALE; PENTOSTATIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032758108     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199911)33:5<476::AID-MPO7>3.0.CO;2-Q     Document Type: Article

References (29)

1. Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13:570-574.
2. Jalyesimi IA, Kantarjian HM, Estey EH. Advances in therapy for hairy cell leukemia. A review. Cancer 1993;72:5-16.
3. Kornblau SM, Gandhi V, Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed and refractory acute myelogenous leukemia in adults. Leukemia 1996; 10:1563-1569.
4. Santana VM, Mirro J Jr, Kearns C, Schell MJ, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10:364-370.
5. Urba WJ, Baseler MW, Kopp WC, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 198973:38-46.
6. Saven A, Foon KA, Piro LD. 2-Clorodeoxyadenosine-induced remissions in Langerhans-cell histiocytosis. Ann Intern Med 1994; 121:430-432.
7. McCowage GB, Frush DP, Kurtzberg J. Successful treatment of two children with Langerhans cell histiocytosis with 2-deoxycoformycin. J Pediatr Hematol Oncol 1996;18:154-158.
8. Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol 1997;29: 288-292.
9. Dimopoulos MA, TheodorakisM, Kostis E, et al. Treatment of Langerhans-cell histiocytosis with 2-deoxychloroadenosine. Leuk Lymph 1997;25:187-189.
10. Betticher DC, Fey MF, von Rohr A, et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant Lymphomas and chronic and acute leukemias. Ann Oncol 1994;5:57-64.
11. Vahdat L, Wong EG, Wile MJ, et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994;84:3429-3434.
12. Lombardi A, El Hachem MC, Rana I, et al. 2-Deoxycoformycin as treatment in refractory Langerhans cell histiocytosis. J Pediatr 1997;130:330.
13. Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance. Br J Cancer 1994;70(Suppl XXIII):S29-S33.
14. Ladisch S, Gadner H, Maurico A, et al. LCH-1: a randomised trial of etoposide versus vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994;23:107-110.
15. Gadner H, Heitger A, Grois N. A treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994;23: 72-80.
16. Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood. Results from the Italian Cooperative AIEOP-CNR-HX '83 study. Med Pediatr Oncol 1993;21:259-264.
17. The French Langerhans Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans cell histiocytosis. 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75: 17-24.
18. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994;120:784-791.
19. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5-nucleotidase to the chemotherapeutic efficacy of 2 chlorodeoxyadenosine. Blood 1993;81:597-601.
20. Arner ESJ. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leuk Lymph 1996;21:225-231.
21. Lillemark J, Petterson B, Juliusson G. The relationship between plasma 2-chloro-2-deoxyadenosine (CdA) and cellular CdA nucleotides (CdAn) after intermittent and continuous i.v. infusion in patients with chronic lymphocytic leukemia (abstract). Blood 1991;78(Suppl):33a.
22. Lillemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2 deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992;10:1514-1518.
23. Lillemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2-deoxyadenosine (CdA) in cerebrospinal fluid (CSF). Blood 1992; 80:11874.
24. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:339-357.
25. Van Den Neste E, Delannoy A, Vandercam B, et al. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996;56:235-240.
26. Schirmer M, Hilbe W, Geisen F, et al.T cells and natural killer cells after treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Acta Haematol 199797:180-183.
27. Dann EJ, Anastasi J, Larson RA. High dose Cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol 1998;16:1498-1504.
28. Saven A. Comparative efficacy of the newer nucleosides (Fludarabine, 2-deoxycoformycin and 1-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies. Semin Hematol 1993;30(Suppl 6):31-33.
29. Johnston JB, Williams M, Verburg L, et al. Combination therapy with deoxyadenosine plus 2-deoxycoformycin and alkylating agents. Proc Annu Meet Am Assoc Cancer Res 1993;34:A1765.